ERBB2 Primary Antibody
|Aliases||NEU; HER2; TKR1; CD340; HER-2|
|Formulation||Ascitic fluid containing 0.03% sodium azide.|
|Immunogen||Purified recombinant fragment of human ERBB2(aa750-987) expressed in E. Coli.|
|Shipping Information||This product will ship in a box containing blue ice at a temperature of 4°C. Learn More|
|IHC_P(Immunohistochemistry)||1/200 - 1/1000|
|FCM (Flow Cytometry)||1/200 - 1/400|
|WB (Western Blot)||1/500 - 1/2000|
ERBB2: v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian). This gene encodes a member of the epidermal growth factor (EGF) receptor family of receptor tyrosine kinases. This protein has no ligand binding domain of its own and therefore cannot bind growth factors. However, it does bind tightly to other ligand-bound EGF receptor family members to form a heterodimer, stabilizing ligand binding and enhancing kinase-mediated activation of downstream signalling pathways, such as those involving mitogen-activated protein kinase and phosphatidylinositol-3 kinase. Allelic variations at amino acid positions 654 and 655 of isoform a (positions 624 and 625 of isoform b) have been reported, with the most common allele, Ile654/Ile655, shown here. Amplification and/or overexpression of this gene has been reported in numerous cancers, including breast and ovarian tumors. Alternative splicing results in several additional transcript variants, some encoding different isoforms and others that have not been fully characterized.
|References (references)||1. RR Mehta, JH McDermott, TJ Hieken, et al. J. Clin. Oncol. 1998;16:2409 - 2416. |
2. Hideko Y, Vered S, and Daniel F.H, et al. J. Clin. Oncol.2001;19:2334 - 2356.
3. Magali F, Kamel H, Cile B, et al. Clinical Cancer Research. 2000;6:4745-4754.